Does Insurance Cover GLP-1s in 2026? (State-by-State Guide)

Getting insurance to cover GLP-1 medications feels like navigating a maze designed to make you give up. One plan covers Wegovy but not Zepbound (a dual GIP/GLP-1 receptor agonist). Another covers Ozempic for diabetes but denies it for weight loss, even though you have both conditions. Medicare says no for weight loss alone without qualifying comorbidities. Medicaid depends on which state you live in. Your employer plan requires three prior authorizations before approval.

The confusion is not accidental. Insurance coverage for GLP-1 medications represents one of the most complex prescription drug scenarios in American healthcare. The same drug, same dose, same patient, but whether you pay $50 or $1,400 depends entirely on what your doctor writes on the prescription.

The insurance landscape changed dramatically in 2026. Medicare launched a new program offering $50 copays for some beneficiaries. Several states eliminated Medicaid coverage entirely on January 1st. Commercial plans tightened restrictions while simultaneously facing pressure from employers to control costs. At the same time, direct-to-consumer options emerged as real alternatives.

This guide breaks down exactly what Medicare covers, which 13 states still offer Medicaid coverage, how to get commercial insurance approval on the first try, what to do when denied, and when paying cash costs less than using insurance.

Medicare Coverage 2026: The Medicare GLP-1 Bridge and BALANCE Model

Medicare historically excluded drugs prescribed "solely for weight loss" under a 2003 law. That changed in July 2026 when CMS launched the Medicare GLP-1 Bridge, a short-term demonstration program providing eligible Part D beneficiaries access to Wegovy and Zepbound at reduced cost. This runs through December 2026 and serves as a bridge to the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive health) Model, which launches in Medicare Part D in January 2027. This isn't full Medicare coverage for everyone, but a demonstration program with specific eligibility criteria and phased rollout.

Medicare GLP-1 Bridge & BALANCE Model Eligibility (3 Phases)

Medicare GLP-1 Bridge (July 2026 - December 2026):

• BMI 27+ with established cardiovascular disease (prior heart attack, stroke, documented CAD) OR
• BMI 27+ with prediabetes (A1C 5.7-6.4% documented in past 6 months) OR
• BMI 30+ with documented hypertension (BP 140/90+ on two readings or on medication)

Phase 2 (January 2027 - December 2027):

• BMI 30+ without additional comorbidities OR
• BMI 27+ with chronic kidney disease Stage 3 (eGFR 30-60) OR
• BMI 27+ with heart failure (NYHA Class II-III)

Phase 3 (2028+): Expansion criteria based on Phase 1-2 results, possibly including BMI 25+ with metabolic syndrome.

Real-World Examples:

Sarah, age 68: BMI 28, type 2 diabetes (A1C 7.2%), hypertension. Qualifies for Medicare GLP-1 Bridge (BMI 27+ with hypertension). Gets Wegovy at $50 copay.

James, age 71: BMI 32, no other conditions. Does NOT qualify Bridge, must wait until BALANCE model(January 2027) when obesity alone becomes sufficient.

Medicare BALANCE Pricing

• Beneficiary copay: $50/month flat rate (any GLP-1 medication)
• Medicare pays: $245/month to manufacturers
• Copay counts toward: Annual out-of-pocket maximum ($2,000 in 2026)

What Medicare Still Doesn't Cover:

• Weight loss without qualifying comorbidities
• Compounded semaglutide/tirzepatide (not FDA-approved)
• Beneficiaries who achieve goal weight and no longer meet BMI criteria

Traditional Medicare Part D coverage for diabetes continues unchanged. The Medicare GLP-1 Bridge and BALANCE Model only affect weight loss indications.

Medicaid Coverage: State-by-State Breakdown

Medicaid coverage varies dramatically because each state sets its own rules. As of February 2026, only 13 states cover GLP-1 medications for weight loss, down from 16 after California, New Hampshire, Pennsylvania, and South Carolina eliminated coverage for obesity treatment (KFF, Medicaid Coverage of and Spending on GLP-1s, January 2026). Michigan has also restricted GLP-1 coverage for weight loss, though the extent of its policy change should be confirmed against the Michigan MDHHS pharmacy bulletin.

Why States Eliminated Coverage

California (Medi-Cal): Eliminated all GLP-1 weight loss coverage for adults 21+ effective January 1, 2026. Wegovy, Zepbound, and Saxenda were removed from the Medi-Cal Rx Contract Drugs List for weight loss indications. Coverage continues for type 2 diabetes, cardiovascular disease, and sleep apnea with prior authorization.

Pennsylvania: Eliminated Medicaid coverage of GLP-1s for obesity treatment in adults effective January 1, 2026, while continuing coverage for diabetes and other medically accepted indications with prior authorization. The state cited rising costs - GLP-1 prescriptions grew from $223 million in 2022 to $650 million in 2024 - as the primary driver.
‍
Sources:
‍
PA Medical Assistance Bulletin, Nov 24 2025

Spotlight PA, Dec 2025

Penn LDI

Michigan: Published updated pharmacy guidance restricting GLP-1 coverage for weight loss, with transition rules for existing patients. The full scope of the restriction should be verified against the MDHHS pharmacy bulletin before publishing specific details. (Referenced in GLP Winner state coverage analysis)

Table 1: States With Medicaid GLP-1 Coverage (February 2026)

How to Check Your State's Coverage

1. Visit your state Medicaid website
2. Search for "Preferred Drug List" or "PDL"
3. Look for "GLP-1 Receptor Agonists" category
4. Download clinical criteria document for PA requirements
5. Note: Medicaid managed care plans may have different formularies than state PDL

Commercial Insurance: Prior Authorization Requirements

A significant and growing share of commercial plans cover GLP-1s for weight loss (per the KFF 2025 Employer Health Benefits Survey, 43% of firms with 5,000+ employees reported covering GLP-1s for weight loss), but nearly all require prior authorization. Approval rates improve significantly when complete documentation is submitted on the first try.

What Prior Authorization Requires

Prior authorization criteria vary by insurance plan and payer. The requirements listed below reflect common documentation standards but may not apply to all plans. Confirm specific criteria directly with your insurer.

Medical Criteria (Must Meet All):

• BMI 30+ OR BMI 27+ with weight-related comorbidity
• Documented comorbidity: type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, sleep apnea, PCOS, or prediabetes
• Age 18+ (some plans 12+ for pediatric obesity)
• Documented diet and exercise failure for 3-6 months
• No contraindications (no MTC history, MEN2 syndrome, not pregnant)

Documentation Checklist:

✅ BMI Measurements: Two separate measurements 30+ days apart, both meeting threshold, taken within past 90 days

✅ Comorbidity Proof: ICD-10 diagnosis codes plus supporting labs (A1C for diabetes/prediabetes, lipid panel for dyslipidemia, sleep study for OSA)

✅ Diet/Exercise Documentation: Choose one:

• Commercial program enrollment (Weight Watchers, Noom) with 3-6 month attendance records
• Nutritionist visits (minimum 3-6 visits over 3-6 months) with SOAP format notes
• Physician-supervised program with monthly weigh-ins and documented counseling

✅ Labs: A1C (all patients), comprehensive metabolic panel, lipid panel, TSH, pregnancy test (women of childbearing age)

✅ Physician Letter of Medical Necessity: Must address why GLP-1 appropriate, expected benefits beyond weight loss, why alternatives insufficient, monitoring plan

Understanding Formulary Tiers and Copays

Your copay depends entirely on which tier your plan places GLP-1s:

• Tier 2 (Preferred Brand): Typically lower copay (rare for GLP-1s; exact amount varies by plan)
• Tier 3 (Non-Preferred Brand): Typically moderate copay (most common placement; exact amount varies by plan)
• Tier 4 (Specialty): Typically percentage-based coinsurance of list price (exact percentage varies by plan)
• Tier 5 (Non-Covered): 100% = you pay full $1,349

Important: Your actual copay depends on your specific plan's formulary tier placement and cost-sharing structure. Contact your insurer or check your plan's Summary of Benefits to find the tier for your specific GLP-1 medication.

Step Therapy Requirements

Many plans require trying cheaper medications first:

Typical Sequence:

1. Step 1: Phentermine or metformin for 3 months
2. Step 2: Combination therapy (Qsymia, Contrave) for 3 months
3. Step 3: GLP-1 approval only after Steps 1-2 fail

Step Therapy Exceptions:

• A1C over 9%
• BMI over 40
• Documented contraindication to Step 1 medication
• Previous intolerance with documented side effects

How to Get Prior Authorization Approved

These steps may improve the likelihood of approval but do not guarantee coverage. Approval decisions remain at the discretion of the individual insurance plan.

Sample Physician Letter That Gets Approved

[Date]

[Insurance Company]

Prior Authorization Department

Re: Prior Authorization for Wegovy (semaglutide) 2.4mg weekly

Patient: [Name], DOB: [Date], Policy ID: [Number]

Dear Review Team,

I request coverage for Wegovy for [patient name], who meets all medical necessity criteria.

CLINICAL PRESENTATION:

- BMI: 35.2 (10/15/25) and 35.4 (11/20/25)

- Height: 5'6", Weight: 218 lbs

- Type 2 diabetes: A1C 8.4% (11/18/25), ICD-10: E11.9

- Hypertension: BP 148/94 despite medications, ICD-10: I10

- Dyslipidemia: LDL 158 mg/dL, triglycerides 210 mg/dL, ICD-10: E78.5

PREVIOUS TREATMENT:

1. Weight Watchers (6 months): 218→215 lbs (1.4% loss, <5% threshold)

2. Registered Dietitian (4 visits, 9/12-12/5/25): 1,500 cal/day diet prescribed

3. Exercise program: 150 min/week prescribed, patient averaged 140 min/week

4. Metformin 1000mg BID: A1C improved 9.1%→8.4%, weight unchanged

MEDICAL NECESSITY:

Despite 6 months intensive lifestyle modification, patient achieved <5% weight loss. GLP-1 therapy expected to provide:

- 10-15% weight loss (STEP trial data)

- A1C reduction 1.5-2 percentage points

- BP reduction 5-7 mmHg

- Cardiovascular risk reduction

MONITORING PLAN:

- Monthly visits months 1-3 (titration)

- Quarterly visits thereafter

- Labs every 3 months (A1C, CMP, lipids)

Thank you for considering this request.

Sincerely,

[Physician Name, MD]

[NPI Number]

Why This Works: Specific measurements with dates, ICD-10 codes, objective documentation proving diet/exercise failure, clinical rationale for expected benefits.

Timeline Expectations

• Submit PA: Day 0
• Insurance review: Days 1-7
• Decision: Days 5-10 (standard), 72 hours (expedited)
• If denied: File appeal within 180 days

When Insurance Denies: The Appeals Process

A meaningful percentage of first denials get overturned on appeal when additional objective evidence is provided. Understanding why you were denied is critical.

Table 2: Appeal Success Rates by Denial Reason (2025-2026)

How to File a Strong Appeal

Step 1: Request Complete Denial Documentation (Days 1-7)

• Written denial letter
• Specific policy language cited
• PA submission that was denied

Step 2: Gather Additional Evidence (Days 7-30)

For "Insufficient Documentation":

• Nutritionist visit notes in SOAP format
• Commercial program: enrollment contract + attendance logs + weigh-in records
• Physician monthly weights for 3-6 months
• Food diary or app logs

For "Criteria Not Met":

• Additional comorbidity diagnoses
• Updated BMI if weight increased
• More recent labs showing disease progression

For "Step Therapy Not Completed":

• Previous medication trial records
• Contraindication documentation
• Intolerance records with side effects documented

Step 3: Submit Written Appeal (Days 30-45)

Include:

• Appeal letter addressing specific denial reason
• All supporting documentation
• Copy of denial letter
• Copy of original PA

Step 4: External Review if Denied Again (Day 75+)

File with state insurance department (not insurance company). Independent reviewer evaluates case. Decision is binding in most states. Success rate: External review can be effective for legitimate disputes

Real Appeal Case Study

Initial Denial: "Patient has not documented failure of diet and exercise for minimum 6 months."

Original submission: Physician letter stating "patient reports trying diet and exercise for past year."

Appeal strategy: Gathered objective documentation:

• MyFitnessPal food logs (6 months, 1,400 cal/day average)
• Gym membership check-ins (4x/week for 6 months)
• PCP monthly weights: 235→233→234→236→235→234 lbs

Outcome: APPROVED. Insurer accepted objective third-party documentation.

Key takeaway: "Patient reports" never sufficient. Need objective records.

Direct-to-Consumer Alternatives (Bypassing Insurance)

For many patients, bypassing insurance costs less than using insurance, especially with high deductibles or specialty tier copays.

When Cash Pay Costs Less Than Insurance

Scenario 1: High Deductible Health Plan

• HDHP with $5,000 deductible
• Before deductible: pay $1,349/month
• Months 1-4: $1,349 × 4 = $5,396
• Manufacturer program: $199-$349 × 12 = $2,388-$4,188
• Savings: $1,208-$3,008

Scenario 2: Specialty Tier Coinsurance

• Plan places GLP-1 on Tier 4: 25% coinsurance
• Monthly copay: 25% × $1,349 = $337
• Annual: $337 × 12 = $4,044
• TrumpRx: $245 × 12 = $2,940
• Savings: $1,104

TrumpRx Platform (Launched February 2026)

How It Works:

TrumpRx (TrumpRx.gov) is a government navigator portal — not a telehealth platform. It does not provide physician consultations, write prescriptions, or ship medications. Instead, it connects patients to manufacturer direct-to-consumer programs at negotiated prices. You still need a valid prescription from your own healthcare provider.

Pricing:

• Injectable semaglutide (Wegovy/Ozempic): ~$350/month
• Injectable tirzepatide (Zepbound): ~$346/month
• Oral GLP-1 starting doses (if approved): ~$150/month

Note: Prices are set by manufacturer agreements and may fluctuate. TrumpRx redirects you to manufacturer websites to complete purchase. (Source: https://www.wtwco.com/en-us/insights/2025/12/trumprx-and-glp-1s-what-this-means-for-drug-pricing-and-employer-strategies)

Manufacturer Direct Programs

Novo Nordisk (Wegovy):

• Injectable: Months 1-2 at $199, Months 3+ at $349
• Oral pill: $149 (Jan-June 2026 launch pricing), $299 (July 2026+)
• Eligibility: No insurance coverage OR commercial insurance patients
• Enrollment: WegovyDirect.com, prescription sent to Novo specialty pharmacy

Eli Lilly (Zepbound):

• Vials: $399-$549/month (requires drawing medication, self-injecting)
• Pens: Not available through direct program
• Why vials: 60-70% cheaper to manufacture, makes medication accessible
• Enrollment: LillyDirect.com, includes video tutorials on vial injection

Compounded Semaglutide/Tirzepatide

The FDA shortage designations for semaglutide and tirzepatide have been resolved (semaglutide: February 2025, tirzepatide: December 2024). Mass compounding of exact copies of these medications is no longer permitted under the shortage exemption. Patient-specific compounding through licensed 503A pharmacies may still be available with documented medical necessity from a prescriber - consult your provider.

Important: Compounded medications are not reviewed by the FDA for safety, quality, or efficacy. GLP-1 therapy should only be used under the guidance of a licensed healthcare provider who can evaluate your medical history and determine whether this treatment is appropriate for you.

Pricing: $197-$397/month through telehealth platforms (Hims/Hers, Ro, Henry Meds)

Quality Considerations:

• Verify that the compounding pharmacy is a licensed 503A facility operating under current FDA guidelines for patient-specific compounding. 503B outsourcing facilities are no longer permitted to compound copies of semaglutide or tirzepatide following resolution of the FDA shortage designations.
• Request certificate of analysis (batch testing)
• Check USP 797 compliance (sterile compounding standards)

Risk: FDA can end shortage designations anytime, which requires compounding pharmacies to discontinue manufacturing to comply with regulations, typically with a 60-90 day wind-down period.

Can I appeal if insurance covers diabetes but denies weight loss?

Yes. If you have both diabetes and obesity, you have options:

1. Accept diabetes coverage (Ozempic/Mounjaro at lower doses)
2. Appeal for weight loss dose citing A1C + weight loss dual benefit
3. Use cardiovascular indication if you have established CVD

Can I use manufacturer coupons with insurance?

• Commercial insurance: Usually yes (except plans with coupon accumulator programs)
• Medicare: No (federal anti-kickback law prohibits)
• Medicaid: No (federal law prohibits)
• 13 states banned coupon accumulators: Check if yours protects coupon use

What if I move to a state without Medicaid coverage?

Coverage ends when you establish new residency. Options:

1. Stockpile 90-day supply before moving
2. Apply for marketplace insurance (moving triggers special enrollment)
3. Use manufacturer programs temporarily ($199-$549/month)

2027 and Beyond: What's Coming

Medicare Drug Price Negotiation

• January 2027: Negotiated GLP-1 prices take effect
• Expected reduction: 40-60% from current list prices
• Wegovy: $1,349 → estimated $540-$810
• Beneficiary impact: Lower Part D copays, possibly lower Bridge/BALANCE copays

Medicaid Coverage Expansion

CMS offering enhanced federal matching (90% federal vs typical 50-78%) for states covering obesity treatments 2027-2029. Texas, Florida, Georgia, Ohio, North Carolina considering expansion.

New Oral GLP-1s

Orforglipron (Eli Lilly) - Expected Q2 2026 Approval:

• No fasting required (vs oral Wegovy needs empty stomach)
• Once-daily dosing
• Expected $500-$700/month (cheaper than injectable)

The Bottom Line

Insurance coverage for GLP-1 medications in 2026 requires understanding the system:

Medicare: Medicare GLP-1 Bridge offers $50 copays starting July 2026 for BMI 27+ with qualifying comorbidities (Phase 1: CVD, prediabetes, hypertension). Phase 2 (January 2027) expands to BMI 30+ without additional comorbidities.

Medicaid: Only 13 states cover weight loss indication. California, New Hampshire, Pennsylvania, and South Carolina eliminated coverage for obesity treatment per (KFF). Michigan restricted but may not have fully eliminated coverage.

Commercial Insurance: A growing share of plans cover with prior authorization. Approval rates improve significantly with complete documentation: two BMI measurements, comorbidity labs, 3-6 month diet failure proof, physician letter. Missing any element leads to denial.

Appeals: A meaningful percentage of denials are overturned on appeal when the specific denial reason is addressed with additional objective evidence. External review through your state insurance department is an option for legitimate disputes.

Direct-to-Consumer: Manufacturer programs ($199-$549/month) and the TrumpRx portal (~$346-$350/month) often cost less than insurance with high deductibles or specialty tier copays. Compounded options ($197-$397/month) may be available through 503A pharmacies with documented medical necessity — shortages have been resolved and the regulatory landscape is evolving.